Prospective Clinical Trial to Compare Vincristine and Vinblastine in a COP-Based Protocol for Lymphoma in Cats
Authors:
- 1 January 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 27 (1) , 134-140
Abstract
Background: Current standard chemotherapy protocols for lymphoma in cats carry risks of gastrointestinal toxicity, which can decrease quality of life and complicate response assessment. Protocols with less gastrointestinal toxicity may improve treatment tolerance. Hypothesis/Objectives: The study purpose was to compare response rate, outcome, and toxicity between cats that received vincristine or vinblastine as part of combination chemotherapy for lymphoma. We hypothesized that vinblastine would have similar efficacy, but less gastrointestinal toxicity, compared with vincristine. Animals: Forty client-owned cats with confirmed diagnosis of lymphoma. Methods: Cats were randomized to 1 of 2 treatment arms and received weekly COP-based chemotherapy for 6 months or until disease progression. Response rate, progression-free survival (PFS), lymphoma-specific survival (LSS), and incidence and severity of gastrointestinal and hematologic toxicity were compared between arms. Arm cross-over occurred if specific gastrointestinal toxicity criteria were noted. Results: Cats in both arms had similar response rates, PFS, and LSS (48 versus 64 days, P = .87; 139 versus 136 days, P = .96). Cats that received vincristine were significantly more likely to switch arms based on gastrointestinal toxicity than cats that received vinblastine (44.4 versus 10.5%, P = .02). Lower baseline weight was significantly negatively associated with PFS and LSS (P = .01, P = .003, respectively). Baseline anemia was significantly negatively associated with LSS (P = .04). Conclusions and Clinical Importance: Results suggest that vinblastine is a reasonable alternative to vincristine in the treatment of some cats with lymphoma. Baseline body weight remains a significant prognostic factor for cats with lymphoma.Keywords
Funding Information
- Clinical Oncology Research Fund of the Veterinary Hospital of the University of Pennsylvania
- University of Pennsylvania School of Veterinary Medicine Department of Clinical Studies Research Grant
This publication has 24 references indexed in Scilit:
- Prognostic Significance of Weight Changes during Treatment of Feline LymphomaJournal of Feline Medicine and Surgery, 2011
- Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus documentVeterinary and Comparative Oncology, 2010
- Toxicities and salvage therapy following overdose of vinblastine in a catJournal of Small Animal Practice, 2010
- Prevalence and prognostic impact of hypocobalaminemia in dogs with lymphomaJournal of the American Veterinary Medical Association, 2009
- Relationships between Low Serum Cobalamin Concentrations and Methlymalonic Acidemia in CatsJournal of Veterinary Internal Medicine, 2009
- Survival Analysis of 97 Cats with Nasal Lymphoma: A Multi-Institutional Retrospective Study (1986–2006)Journal of Veterinary Internal Medicine, 2009
- A prospective investigation of the prevalence and prognostic significance of weight loss and changes in body condition in feline cancer patientsJournal of Feline Medicine and Surgery, 2007
- Feline epitheliotrophic T‐cell lymphoma with paraneoplastic eosinophilia – immunochemotherapy with vinblastine and human recombinant interferon α2bVeterinary and Comparative Oncology, 2004
- Chemotherapy with Cyclophosphamide, Vincristine, and Prednisolone (COP) in Cats with Malignant Lymphoma: New Results with an Old ProtocolJournal of Veterinary Internal Medicine, 2002
- A Comparison of Doxorubicin and COP for Maintenance of Remission in Cats With LymphomaJournal of Veterinary Internal Medicine, 1996